UNASSIGNED: Disease overview: @entity784 are a heterogenous group of T-cell lymphoproliferative disorders involving the skin, the majority of which may be classified as @entity4888 ( @entity4888 ) or @entity4889 ( @entity4889 ). DIAGNOSIS: The diagnosis of @entity4888 or @entity4889 requires the integration of clinical and histopathologic data. Risk-adapted therapy: TNMB ( @entity5 , node, @entity3 , blood) staging remains the most important prognostic factor in @entity4888 / @entity4889 and forms the basis for a "risk-adapted," multidisciplinary approach to treatment. For @entity1 with disease limited to the skin, expectant management or skin-directed therapies is preferred, as both disease-specific and overall survival for these @entity1 is favorable. In contrast, @entity1 with @entity5 with significant nodal, visceral, or blood involvement are generally approached with biologic-response modifiers or histone deacetylase inhibitors before escalating therapy to include systemic, single-agent chemotherapy. In highly-selected @entity1 , allogeneic stem-cell transplantation may be considered, as this may be curative in some @entity1 . Am. J. Hematol., 2015.    2015 Wiley Periodicals, Inc.

XXXX : 2016 update on diagnosis, risk-stratification, and management.

@entity4888 :: ('MESH:D009182', 'Disease') :: ['MF', 'Mycosis Fungoides'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4889 :: ('MESH:D018455', 'Disease') :: ['SS', 'S  zary Syndrome'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'advanced-stage disease'] @entity784 :: ('MESH:D016399', 'Disease') :: ['Cutaneous T-cell lymphomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity784 :: (MESH:D016399,Disease) :: ['Cutaneous T-cell lymphoma']
